Final month, President Joe Biden formally introduced his intention to reclassify marijuana underneath the Managed Substances Act. This vital transfer would shift marijuana from Schedule I — probably the most restrictive class — to Schedule III. This reclassification would place marijuana in the identical class as anabolic steroids, ketamine, and testosterone, recognizing its medical advantages whereas acknowledging some threat of abuse.
Proper now, marijuana has a higher-level classification than fentanyl and methamphetamine — the 2 medication driving America’s overdose epidemic,” Biden famous in a submit on X, previously Twitter. “That simply doesn’t add up.”
Federal Shift and Its Impression on Kentucky
Reclassifying marijuana as a Schedule III drug doesn’t equate to federal legalization. Nevertheless, it may scale back the tax burden on hashish companies working in states the place marijuana is authorized for leisure or medicinal use. This variation is especially related for companies in Kentucky getting ready for the launch of the state’s medical hashish program in early 2025.
“The Drug Enforcement Administration’s reported reclassification of marijuana from a Schedule I to a Schedule III managed substance will seemingly have vital tax implications for potential licensees,” said Brice Mitchell, spokesperson for the Kentucky Cupboard for Well being and Household Providers.
At the moment, underneath federal regulation (26 U.S. Code §280E), marijuana companies can’t deduct their enterprise bills on account of its Schedule I classification. Rescheduling to Schedule III would get rid of this prohibition, permitting these companies to deduct their bills. This variation may considerably scale back their taxes by 40% to 70%, in response to a CBS Information report. In 2022, compliant hashish companies paid an estimated $1.8 billion in extra taxes.
Advantages Past Tax Reduction
The reclassification can be anticipated to ease banking restrictions. Banks and bank card firms, at present cautious of hashish companies on account of authorized ambiguities, might grow to be extra prepared to have interaction with the trade.
Moreover, reclassification may gain advantage analysis. As Mitchell defined, “At the moment, the Drug Enforcement Administration is required to set annual manufacturing quotas for Schedule I managed substances manufactured to be used in authorised analysis. DEA isn’t required to set annual manufacturing quotas for Schedule III managed substances. In consequence, there could also be extra marijuana accessible for authorised federal analysis.
General, whereas reclassifying marijuana to Schedule III isn’t the identical as legalization, it represents a big shift in federal coverage that would have widespread constructive implications for the hashish trade, significantly in states like Kentucky getting ready to develop their medical hashish packages.
